Applications of CRISPR-Cas9 Gene Editing Technology in Treatment of Sickle Cell Disease

CRISPR-Cas9 gene editing technology has emerged as a breakthrough tool in the 21st century for biomedical research and clinical treatment. This approach allows the precise editing of only certain gene fragments, which can potentially correct or replace a mutation that causes disease. Its applications span personalized medicine, regenerative medicine, and the prevention and control of genetic diseases. Among many such diseases, sickle cell disease is one of the interesting targets amenable to CRISPR-Cas9 treatment. A point mutation in the gene coding for β-globin is responsible for the aberrant hemoglobin synthesis that leads to a myriad of severe symptoms in sickle cell disease. The main two approaches in treating sickle cell disease using CRISPR-Cas9 are correcting the mutation in the β-globin gene or reactivating the expression of fetal hemoglobin to blunt disease manifestations. But this technology is riddled with huge challenges: it has off-target effects and it raises ethical issues regarding gene editing in human embryos. This paper will discuss the use of CRISPR-Cas9 in the treatment of sickle cell disease, its application mechanisms, and the challenges that need to be overcome to realize its full therapeutic potential.